유전성 검사 시장 규모, 점유율, 동향 분석 보고서 : 질환 유형별, 기술별, 지역별, 부문별 예측(2025-2033년)
Hereditary Testing Market Size, Share & Trends Analysis Report By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), By Technology (Cytogenetic, Biochemical, Molecular Testing), By Region, And Segment Forecasts, 2025 - 2033
상품코드
:
1888723
리서치사
:
Grand View Research
발행일
:
2025년 11월
페이지 정보
:
영문 270 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
유전성 검사 시장 요약
세계의 유전성 검사 시장 규모는 2024년에 161억 6,000만 달러로 추정되며, 유전성 질환 및 관련된 만성질환 유병률 증가에 의해 2025년부터 2033년까지 CAGR 14.42%로 성장하여 2033년까지 526억 6,000만 달러에 달할 것으로 예측됩니다.
유전성 암, 심혈관질환, 대사증후군, 희귀 유전적 이상 진단을 받는 환자가 증가함에 따라 조기 및 정확한 검출에 대한 수요가 급증하고 있습니다.
많은 유전성 질환은 대부분 후천적으로 발병하는 경우가 많기 때문에 예방, 경과 관찰, 의학적 판단에 있어 조기 검사가 필수적입니다. 또한, 신생아 및 영아 선별 검사의 증가로 인해 이전에는 발견되지 않았던 수많은 유전적 이상이 밝혀졌습니다. 임상적 인식이 높아짐에 따라 의사들은 정기적인 위험 평가의 일환으로 유전자 검사를 더 자주 권장하고 있습니다. 또한, 인구 고령화에 따라 특정 암 및 신경 퇴행성 질환과 같은 노화 관련 유전성 질환이 더욱 보편화되고 있으며, 이는 추가적인 유전적 평가를 촉진하고 있습니다. 이러한 요인들이 결합되어 증상이 나타나기 전에 건강 위험을 식별하는 데 있어 유전성 검사의 중요한 역할을 강조하며 지속적인 시장 성장을 주도하고 있습니다.
목차 제1장 유전성 검사 시장 : 조사 방법과 범위
제2장 유전성 검사 시장 : 주요 요약
시장 개요
질환 유형별 기술 개요
경쟁 구도 개요
제3장 유전성 검사 시장 변수, 동향 및 범위
시장 세분화와 범위
시장 계통 전망
시장 역학
시장 성장 촉진요인 분석
DNA 검사 키트 판매 및 수요 증가
여성 생식 건강에 관한 상업 환경의 지속적인 발전
시퀀싱 비용 하락과 그에 따른 유전자 검사 등록 확대
시장 성장 억제요인 분석
DNA 검사에 관한 윤리적·임상적 문제
DTC 유전자 검사 이용에 관한 규제상 과제
시장 기회 분석
유전성 질환 발생률 증가
조기 및 비침습적인 태아 검사 시술에 대한 수요의 존재
유전체학 밸류체인 전체의 단편적인 포인트 솔루션의 도입
Porter's Five Forces 분석
PESTLE 분석
파이프라인 분석
제4장 유전성 검사 시장 : 질환 유형별 추정·동향 분석
유전성 검사 시장 : 질환 유형별 변동 분석
유전성 암 검사
유방암
폐암
대장암
자궁경부암
난소암
전립선암
위암
악성 흑색종
육종
자궁 암
췌장암
기타
유전성비 암 검사
유전자 검사
착상전 유전자 진단 및 스크리닝
비침습적 산전 검사(NIPT) 및 보인자 스크리닝 검사
신생아 유전자 스크리닝
제5장 유전성 검사 시장 : 기술별 추정·동향 분석
유전성 검사 시장 : 기술별 변동 분석
세포유전학
생화학
분자 검사
제6장 유전성 검사 시장 : 지역별 비즈니스 분석
지역별 시장 개요
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
제7장 경쟁 구도
기업 분류
전략 매핑
신제품 발매
제휴 관계
인수
합작투자
자금 조달
주요 기업의 시장 점유율 분석(2024년)
기업 히트맵 분석
기업 개요
Myriad Genetics, Inc.
Invitae Corporation
Illumina, Inc.
Natera, Inc.
Laboratory Corporation of America Holdings
F. Hoffmann-La Roche Ltd.
Quest Diagnostics Incorporated
COOPERSURGICAL, INC.
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
Twist Bioscience
SOPHiA GENETICS
Fulgent Genetics
MedGenome
CENTOGENE N.V.
KSM
영문 목차
Hereditary Testing Market Summary
The global hereditary testing market size was estimated at USD 16.16 billion in 2024 and is projected to reach USD 52.66 billion by 2033, growing at a CAGR of 14.42% from 2025 to 2033, due to the increasing prevalence of genetic disorders and related chronic conditions. As more individuals are diagnosed with inherited cancers, cardiovascular diseases, metabolic syndromes, and rare genetic abnormalities, the demand for early and accurate detection has surged.
Many hereditary conditions often manifest later in life, making early testing essential for prevention, monitoring, and medical decision-making. Moreover, increased screening of newborns and infants has highlighted a substantial number of genetic abnormalities that previously went undetected. With better clinical awareness, physicians are recommending genetic testing more often as part of routine risk assessment. In addition, as populations age, age-related hereditary conditions-such as certain cancers and neurodegenerative disorders-are becoming more common, encouraging more genetic evaluations. Together, these factors drive sustained market growth by emphasizing the critical role of hereditary testing in identifying health risks before symptoms emerge.
Global Hereditary Testing Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global hereditary testing market report on the basis of disease type, technology, and region.
Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
Hereditary Cancer Testing
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Ovarian Cancer
Prostate Cancer
Stomach/Gastric Cancer
Melanoma
Sarcoma
Uterine Cancer
Pancreatic Cancer
Others
Hereditary Non-cancer Testing
Genetic Tests
Cardiac Diseases
Rare Diseases
Other Diseases
Preimplantation Genetic Diagnosis & Screening
Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
Newborn Genetic Screening
Technology Outlook (Revenue, USD Million, 2021 - 2033)
Cytogenetic
Biochemical
Molecular Testing
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Middle East & Africa
South Africa
UAE
Saudi Arabia
Kuwait
Table of Contents Chapter 1. Hereditary Testing Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Disease Type
1.1.1.2. Technology Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR's Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Hereditary Testing Market: Executive Summary
2.1. Market Snapshot
2.2. Disease Type Technology Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Hereditary Testing Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Increase in sales and demand for DNA test kits
3.4.2. Constantly developing commercial landscape of women's reproductive health
3.4.3. Decline in sequencing cost & consequent expansion of genetic testing registry
3.5. Market Restraint Analysis
3.5.1. Ethical and clinical issues of DNA tests
3.5.2. Regulatory challenges pertaining to use of DTC genetic tests
3.6. Market Opportunity Analysis
3.6.1. Increasing incidence of genetic diseases
3.6.2. Presence of demand for early and non-invasive fetal testing procedures
3.6.3. Introduction of fragmented point-solutions across the genomics value chain
3.7. Porter's Five Forces Analysis
3.8. PESTLE Analysis
3.9. Pipeline Analysis
Chapter 4. Hereditary Testing Market: Disease Type Estimates & Trend Analysis
4.1. Hereditary Testing Market: Disease Type Movement Analysis
4.2. Hereditary Cancer Testing
4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.2. Breast Cancer
4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.3. Lung Cancer
4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.4. Colorectal Cancer
4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.5. Cervical Cancer
4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.6. Ovarian Cancer
4.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.7. Prostate Cancer
4.2.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.8. Stomach/Gastric Cancer
4.2.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.9. Melanoma
4.2.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.10. Sarcoma
4.2.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.11. Uterine Cancer
4.2.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.12. Pancreatic Cancer
4.2.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.13. Others
4.2.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Hereditary Non-cancer Testing
4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.2. Genetic Tests
4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.2.2. Cardiac Diseases
4.3.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.2.3. Rare Diseases
4.3.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.2.4. Other Diseases
4.3.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.3. Preimplantation Genetic Diagnosis & Screening
4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.4. Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.5. Newborn Genetic Screening
4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Hereditary Testing Market: Technology Estimates & Trend Analysis
5.1. Hereditary Testing Market: Technology Movement Analysis
5.2. Cytogenetic
5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Biochemical
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Molecular Testing
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Hereditary Testing Market: Regional Business Analysis
6.1. Regional Market Snapshot
6.2. North America
6.2.1. North America Hereditary Testing Market Estimates and Forecast, 2021 - 2033 (USD Million)
6.2.2. U.S.
6.2.2.1. U.S. Hereditary Testing Market, 2021 - 2033 (USD Million)
6.2.2.2. Key Country Dynamics
6.2.2.3. Regulatory Framework
6.2.2.4. Reimbursement Scenario
6.2.2.5. Competitive Scenario
6.2.3. Canada
6.2.3.1. Canada Hereditary Testing Market, 2021 - 2033 (USD Million)
6.2.3.2. Key Country Dynamics
6.2.3.3. Regulatory Framework
6.2.3.4. Reimbursement Scenario
6.2.3.5. Competitive Scenario
6.2.4. Mexico
6.2.4.1. Mexico Hereditary Testing Market, 2021 - 2033 (USD Million)
6.2.4.2. Key Country Dynamics
6.2.4.3. Regulatory Framework
6.2.4.4. Reimbursement Scenario
6.2.4.5. Competitive Scenario
6.3. Europe
6.3.1. Europe Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.2. UK
6.3.2.1. UK Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.2.2. Key Country Dynamics
6.3.2.3. Regulatory Framework
6.3.2.4. Reimbursement Scenario
6.3.2.5. Competitive Scenario
6.3.3. Germany
6.3.3.1. Germany Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.3.2. Key Country Dynamics
6.3.3.3. Regulatory Framework
6.3.3.4. Reimbursement Scenario
6.3.3.5. Competitive Scenario
6.3.4. Spain
6.3.4.1. Spain Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.4.2. Key Country Dynamics
6.3.4.3. Regulatory Framework
6.3.4.4. Reimbursement Scenario
6.3.4.5. Competitive Scenario
6.3.5. France
6.3.5.1. France Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.5.2. Key Country Dynamics
6.3.5.3. Regulatory Framework
6.3.5.4. Reimbursement Scenario
6.3.5.5. Competitive Scenario
6.3.6. Italy
6.3.6.1. Italy Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.6.2. Key Country Dynamics
6.3.6.3. Regulatory Framework
6.3.6.4. Reimbursement Scenario
6.3.6.5. Competitive Scenario
6.3.7. Denmark
6.3.7.1. Denmark Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.7.2. Key Country Dynamics
6.3.7.3. Regulatory Framework
6.3.7.4. Reimbursement Scenario
6.3.7.5. Competitive Scenario
6.3.8. Sweden
6.3.8.1. Sweden Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.8.2. Key Country Dynamics
6.3.8.3. Regulatory Framework
6.3.8.4. Reimbursement Scenario
6.3.8.5. Competitive Scenario
6.3.9. Norway
6.3.9.1. Norway Hereditary Testing Market, 2021 - 2033 (USD Million)
6.3.9.2. Key Country Dynamics
6.3.9.3. Regulatory Framework
6.3.9.4. Reimbursement Scenario
6.3.9.5. Competitive Scenario
6.4. Asia Pacific
6.4.1. Asia-Pacific Hereditary Testing Market, 2021 - 2033 (USD Million)
6.4.2. Japan
6.4.2.1. Japan Hereditary Testing Market, 2021 - 2033 (USD Million)
6.4.2.2. Key Country Dynamics
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Scenario
6.4.2.5. Competitive Scenario
6.4.3. China
6.4.3.1. China Hereditary Testing Market, 2021 - 2033 (USD Million)
6.4.3.2. Key Country Dynamics
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Scenario
6.4.3.5. Competitive Scenario
6.4.4. India
6.4.4.1. India Hereditary Testing Market, 2021 - 2033 (USD Million)
6.4.4.2. Key Country Dynamics
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Scenario
6.4.4.5. Competitive Scenario
6.4.5. South Korea
6.4.5.1. South Korea Hereditary Testing Market, 2021 - 2033 (USD Million)
6.4.5.2. Key Country Dynamics
6.4.5.3. Regulatory Framework
6.4.5.4. Reimbursement Scenario
6.4.5.5. Competitive Scenario
6.4.6. Thailand
6.4.6.1. Thailand Hereditary Testing Market, 2021 - 2033 (USD Million)
6.4.6.2. Key Country Dynamics
6.4.6.3. Regulatory Framework
6.4.6.4. Reimbursement Scenario
6.4.6.5. Competitive Scenario
6.4.7. Australia
6.4.7.1. Australia Hereditary Testing Market, 2021 - 2033 (USD Million)
6.4.7.2. Key Country Dynamics
6.4.7.3. Regulatory Framework
6.4.7.4. Reimbursement Scenario
6.4.7.5. Competitive Scenario
6.5. Latin America
6.5.1. Latin America Hereditary Testing Market, 2021 - 2033 (USD Million)
6.5.2. Brazil
6.5.2.1. Brazil Hereditary Testing Market, 2021 - 2033 (USD Million)
6.5.2.2. Key Country Dynamics
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Scenario
6.5.2.5. Competitive Scenario
6.5.3. Argentina
6.5.3.1. Argentina Hereditary Testing Market, 2021 - 2033 (USD Million)
6.5.3.2. Key Country Dynamics
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Scenario
6.5.3.5. Competitive Scenario
6.6. Middle East & Africa
6.6.1. Middle East & Africa Hereditary Testing Market, 2021 - 2033 (USD Million)
6.6.2. South Africa
6.6.2.1. South Africa Hereditary Testing Market, 2021 - 2033 (USD Million)
6.6.2.2. Key Country Dynamics
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Scenario
6.6.2.5. Competitive Scenario
6.6.3. Saudi Arabia
6.6.3.1. Saudi Arabia Hereditary Testing Market, 2021 - 2033 (USD Million)
6.6.3.2. Key Country Dynamics
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Scenario
6.6.3.5. Competitive Scenario
6.6.4. UAE
6.6.4.1. UAE Hereditary Testing Market, 2021 - 2033 (USD Million)
6.6.4.2. Key Country Dynamics
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Scenario
6.6.4.5. Competitive Scenario
6.6.5. Kuwait
6.6.5.1. Kuwait Hereditary Testing Market, 2021 - 2033 (USD Million)
6.6.5.2. Key Country Dynamics
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Scenario
6.6.5.5. Competitive Scenario
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.2.1. New Product Launch
7.2.2. Partnerships
7.2.3. Acquisition
7.2.4. Collaboration
7.2.5. Funding
7.3. Key Company Market Share Analysis, 2024
7.4. Company Heat Map Analysis
7.5. Company Profiles
7.5.1. Myriad Genetics, Inc.
7.5.1.1. Company Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Invitae Corporation
7.5.2.1. Company Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Illumina, Inc.
7.5.3.1. Company Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Natera, Inc.
7.5.4.1. Company Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Laboratory Corporation of America Holdings
7.5.5.1. Company Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. F. Hoffmann-La Roche Ltd.
7.5.6.1. Company Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Quest Diagnostics Incorporated
7.5.7.1. Company Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. COOPERSURGICAL, INC.
7.5.8.1. Company Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Agilent Technologies, Inc.
7.5.9.1. Company Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Thermo Fisher Scientific, Inc.
7.5.10.1. Company Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Twist Bioscience
7.5.11.1. Company Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
7.5.12. SOPHiA GENETICS
7.5.12.1. Company Overview
7.5.12.2. Financial Performance
7.5.12.3. Product Benchmarking
7.5.12.4. Strategic Initiatives
7.5.13. Fulgent Genetics
7.5.13.1. Company Overview
7.5.13.2. Financial Performance
7.5.13.3. Product Benchmarking
7.5.13.4. Strategic Initiatives
7.5.14. MedGenome
7.5.14.1. Company Overview
7.5.14.2. Financial Performance
7.5.14.3. Product Benchmarking
7.5.14.4. Strategic Initiatives
7.5.15. CENTOGENE N.V.
7.5.15.1. Company Overview
7.5.15.2. Financial Performance
7.5.15.3. Product Benchmarking
7.5.15.4. Strategic Initiatives
관련자료
